DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$89.53
1.88 (2.14%)
▲
5d:
+2.98%
30d:
+17.26%
90d:
+50.9%
WAIT
LOW Confidence
Analysis Updated: Aug 11, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 7, 2026 at $84.75 · last confirmed Aug 11, 2026
Strength: 6.4/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DXCM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DXCM shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$125.64
Based on 10.7% avg growth
INTRINSIC VALUE TODAY
$78.01
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $89.53, which is considered extended relative to its 30-day fair value range of $71.85 to $83.18. From a valuation perspective, the stock is trading at a premium (Forward PE: 28.6) compared to its historical average (24.3). At these levels, the market is pricing in 5.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DXCM is in a strong uptrend. The price is approaching resistance at $89.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DXCM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DXCM is in a strong uptrend. The price is approaching resistance at $89.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DXCM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$71.85 -
$83.18
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
18.1%
Protect Your Profits
DXCM is technically overbought (RSI 70). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.6% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($93.44)
- NEUTRAL: Trading at premium valuation - market expects 5.7% growth which is achievable
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$71.85 -
$83.18
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$73.24
Resistance Level
$89.56
Current Trend
Strong Uptrend
Technical data as of
Aug 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.65
Wall Street Target
$93.44
(+4.4%)
Revenue Growth (YoY)
13.1%
Earnings Growth (YoY)
43.6%
Profit Margin
20.1%
Valuation Premium vs History
+5.7% premium
PE vs Historical
28.7 vs 24.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.7%
(market-implied from PE analysis)
1-Year Target
$94.63
(+6%)
2-Year Target
$100.03
(+12%)
3-Year Target
$105.73
(+18%)
3-Yr Target (if PE normalizes)
(PE: 29→24)
PE COMPRESSION
$89.66
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.7, Growth: 17.4%)
$144.72
(+62%)
Base:
(SPY PE: 20.2, Growth: 17.4%)
$102.18
(+14%)
Bear:
(PE: 17.2, Growth: 17.4%)
$86.85
(-3%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 33.45 | Current EPS (TTM): $2.62
Bull Case
$114.98
(+28%)
Analyst growth 19.3%, PE expands to 36.8
Base Case
$104.53
(+17%)
Market implied 19.3%, PE stable at 33.5
Bear Case
$59.60
(-33%)
Severe decline -20.0%, PE contracts to 28.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 12, 2026 6:06 AM ET
Data refreshes hourly during market hours. Next update: 7:06 AM
Data refreshes hourly during market hours. Next update: 7:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 38 SELL |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$382 | 51 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 36 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 42 HOLD |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
